Article
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results
Fecha
2014Autor
Ayala-Valdovinos, M.A.
Lemus-Flores, C.
Galindo-García, J.
Sanchez-Chipres, D.
Duifhuis-Rivera, T.
Anguiano-Estrella, R.
Banuelos-Pineda, J.
Rodriguez-Carpena, J.G.
Institución
Resumen
The purpose of this study was to assess the frequency of Theileria equi in horses imported into Mexico. During different stages of quarantine, 348 blood samples were taken from clinically healthy horses imported into Mexico from 2011 to 2013. Nested PCR (nPCR) of the Merozoite Antigen-1 (EMA-1) gene was performed for pathogen detection. In total, 93 horses tested positive for T. equi resulting in a 26.72% frequency with a 95% Confidence Interval (CI) of 22.07-31.37%. This is the first molecular diagnostics study to identify T. equi-positive horses imported into Mexico these results highlight the importance of nPCR analysis for T. equi in clinically healthy imported horses. " Medwell Journals, 2014.",,,,,,"10.3923/javaa.2014.859.863",,,"http://hdl.handle.net/20.500.12104/43052","http://www.scopus.com/inward/record.url?eid=2-s2.0-84906726830&partnerID=40&md5=8dd7106f28740b5ee6b83f619d26e64e",,,,,,"14",,"Journal of Animal and Veterinary Advances",,"859 863",,"13",,"Scopus",,,,,,"Blood samples; Horse; Mexico; nPCR; Theileria equi",,,,,,"Nested PCR detection of Theileria equi infection and frequency in horses imported into Mexico",,"Article"
"41910","123456789/35008",,"Rider, L.G., Ctr. for Biologics Eval. and Res., FDA, Natl. Inst. Arthr. Musculoskel. S., Bethesda, MD, United States, Division of Monoclonal Antibodies, Ctr. for Biologies Eval. and Res., Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, United States; Gurley, R.C., Ctr. for Biologics Eval. and Res., FDA, Bethesda, MD, United States; Pandey, J.P., Medical University of South Carolina, Charleston, SC, United States; García-De La Torre, I., University of Guadalajara, Hosp. General de Occidente de la SS, Guadalajara, Mexico; Kalovidouris, A.E., Indiana University, VA Medical Center, Indianapolis, IN, United States; O'Hanlon, T.P., Ctr. for Biologics Eval. and Res., FDA, Bethesda, MD, United States; Love, L.A., Ctr. for Food and Spec. Nutritionals, FDA, Washington, DC, United States, Natl. Inst. Arthr. Musculoskel. S., NIH, Bethesda, MD, United States; Hennekam, R.C.M., Institute of Human Genetics, Department of Pediatrics, Amsterdam Medical College, Amsterdam, Netherlands; Baumbach, L.L., University of Miami, School of Medicine, Miami, FL, United States; Neville, H.E., University of Colorado, School of Medicine, Denver VA Medical Center, Denver, CO, United States; García, C.A., Louisiana State University, School of Medicine, New Orleans, LA, United States; Klingman, J., Permanente Medical Group, Walnut Creek, CA, United States; Gibbs, M., Permanente Medical Group, Walnut Creek, CA, United States; Weisman, M.H., Univ. of California Medical Center, San Diego, CA, United States; Targoff, I.N., VA Medical Center, Univ. of Oklahoma Med. Sci. Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States; Miller, F.W., Ctr. for Biologics Eval. and Res., FDA, Natl. Inst. Arthr. Musculoskel. S., Bethesda, MD, United States",,"Rider, L.G. Gurley, R.C. Pandey, J.P. García-De La Torre, I. Kalovidouris, A.E. O'Hanlon, T.P. Love, L.A. Hennekam, R.C.M. Baumbach, L.L. Neville, H.E. García, C.A. Klingman, J. Gibbs, M. Weisman, M.H. Targoff, I.N. Miller, F.W.",,"1998",,"Objective. To describe the clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy (IIM) and to compare these with the features of sporadic IIM. Methods. Clinical signs and symptoms, autoantibodies, HLA-DRB1 and DQA1 alleles, and GM/KM phenotypes were compared among 36 affected and 28 unaffected members of 16 unrelated families in which 2 or more blood relatives developed an IIM. In addition, findings in patients with familial IIM were compared with those in 181 patients with sporadic IIM. The families included 3 pairs of monozygotic twins with juvenile dermatomyositis, 11 families with other siblings or relatives with polymyositis or dermatomyositis, and 2 families with inclusion body myositis. Results. The clinical features of familial IIM were similar to those of sporadic IIM, although the frequency of myositis- specific autoantibodies was lower in familial than in sporadic IIM. DRB1*0301 was a common genetic risk factor for familial and sporadic IIM, but contributed less to the genetic risk of familial IIM (etiologic fraction 0.35 versus 0.51 in sporadic IIM). Homozygosity at the HLA-DQA1 locus was found to be a genetic risk factor unique to familial IIM (57% versus 24% of controls; odds ratio 4.2, corrected P = 0.002). Conclusion. These findings emphasize that 1) familial muscle weakness is not always due to inherited metabolic defects or dystrophies, but may be the result of the development of IIM in several members of the same family, and 2) multiple genetic factors are likely important in the etiology and disease expression of familial IIM, as is also the case for sporadic myositis, but DQA1 homozygosity is a distinct risk factor for familial IIM.",,,,,,"10.1002/1529-0131(199804)41:4<710 719",,"41",,"Scopus WOS",,,,,,,,,,,,"Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy",,"Article"
"41900","123456789/35008",,"Vásquez-Garibay, E.M., Instituto de Nutrición Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara Dr. Juan I Menchaca.; Romero-Velarde, E., Instituto de Nutrición Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara Dr. Juan I Menchaca.; Ortiz-Ortega, M.A., Instituto de Nutrición Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara Dr. Juan I Menchaca.; Gómez-Cruz, Z., Instituto de Nutrición Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara Dr. Juan I Menchaca.; González-Rico, J.L., Instituto de Nutrición Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara Dr. Juan I Menchaca.; Corona-Alfaro, R., Instituto de Nutrición Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Hospital Civil de Guadalajara Dr. Juan I Menchaca.",,"Vasquez-Garibay, E.M. Romero-Velarde, E. Ortiz-Ortega, M.A. Gomez-Cruz, Z. Gonzalez-Rico, J.L. Corona-Alfaro, R.",,"2007",,"The prevalence of overweight has significantly increased thorough the world and Mexico is not an exception considering that the National Survey of Nutrition (1999) showed that 19.5% of scholar children in Mexico have overweight and other survey from Mexico City (ENURBAL, 2002) have shown that 17% in the same range of age are obese. Therefore, this clinical guide pretends to be an instrument for supporting the professionals of health for the diagnosis, treatment and prevention of obesity in children using the levels of medical attention. It is known that the treatment is difficult and it requires a full multidisciplinary team of professionals and that the key of prevention is the modification of the sedentary lifestyle and the decrease of energy intake. This guide was elaborated by pediatricians working in nutrition in public and university institutions, family and general physicians and pediatricians with private practice.",,,,,,,,,"http://hdl.handle.net/20.500.12104/40121","http://www.scopus.com/inward/record.url?eid=2-s2.0-34547686365&partnerID=40&md5=ef52d917692cdda2ff0351fdf72e4429",,,,,,"2",,"Revista médica del Instituto Mexicano del Seguro Social",,"173 186",,"45",,"Scopus",,,,,,,,,,,,"Clinical guide for diagnosis, treatment and prevention of overweight and obesity in children [Guía clínica para el diagnóstico, tratamiento y prevención del sobrepeso y la obesidad en pediatría.]",,"Article"
"41907","123456789/35008",,"López-Jiménez, J.J., División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Beltrán-Miranda, C.P., Departamento de Salud y Bienestar, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán, Jalisco, Mexico; Mantilla-Capacho, J.M., Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Esparza-Flores, M.A., Servicio de Hematología, Hospital de Pediatría, Centro Médico de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico; López González, L.C., Servicio de Hematología, Hospital General de Zona No. 46, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico; Jaloma-Cruz, A.R., División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico",,"Lopez-Jimenez, J.J. Beltran-Miranda, C.P. Mantilla-Capacho, J.M. Esparza-Flores, M.A. Lopez Gonzalez, L.C. Jaloma-Cruz, A.R.",,"2009",,"[No abstract available]",,,,,,"10.1111/j.1365-2516.2009.02069.x",,,"http://hdl.handle.net/20.500.12104/40128","http://www.scopus.com/inward/record.url?eid=2-s2.0-70449584734&partnerID=40&md5=837551a435f36cd5a2e0067f252b6e87",,,,,,"6",,"Haemophilia",,"1342 1345",,"15",,"Scopus WOS",,,,,,,,,,,,"Clinical variability of haemophilia A and B in Mexican families by factor V Leiden G1691A, prothrombin G20210A and MTHFR C677T/A1298C",,"Letter"
"41927","123456789/35008",,"Gallant, J.E., Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD, United States; Koenig, E., Instituto Dominicano de Estudio-IDEV, Santo-Domingo, Dominican Republic; Andrade-Villanueva, J., HIV Unit, Hospital Civil de Guadalajara, University of Guadalajara, Guadalajara, Mexico; Chetchotisakd, P., Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; Dejesus, E., Orlando Immunology Center, FL, United States; Antunes, F., Infectious Diseases Department, Hospital de Santa Maria, Lisbon, Portugal; Arasteh, K., EPIMED /Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; Moyle, G., Chelsea and Westminster Hospital, London, United Kingdom; Rizzardini, G., Department of Infectious Diseases, Ospedale Luigi Sacco, Milan, Italy; Fehr, J., Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; Liu, Y., Gilead Sciences, Foster City, CA, United States; Zhong, L., Gilead Sciences, Foster City, CA, United States; Callebaut, C., Gilead Sciences, Foster City, CA, United States; Szwarcberg, J., Gilead Sciences, Foster City, CA, United States; Rhee, M.S., Gilead Sciences, Foster City, CA, United States; Cheng, A.K., Gilead Sciences, Foster City, CA, United States",,"Gallant, J.E. Koenig, E. Andrade-Villanueva, J. Chetchotisakd, P. Dejesus, E. Antunes, F. Arasteh, K. Moyle, G. Rizzardini, G. Fehr, J. Liu, Y. Zhong, L. Callebaut, C. Szwarcberg, J. Rhee, M.S. Cheng, A.K.",,"2013",,"Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro.Methods. An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer of atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in treatment-naive patients. The primary end point was a human immunodeficiency virus type 1 (HIV-1) RNA load of <50 copies/mL at week 48 by the Food and Drug Administration snapshot algorithm; the noninferiority margin was 12%.Results. A total of 692 patients were randomly assigned to a treatment arm and received study drug (344 in the COBI group vs 348 in the RTV group). At week 48, virologic success was achieved in 85% of COBI recipients and 87% of RTV recipients (difference, -2.2% [95% confidence interval, -7.4% to 3.0%]); among patients with a baseline HIV-1 RNA load of >100 000 copies/mL, rates were similar (86% vs 86%). Similar percentages of patients in both groups had serious adverse events (10% of COBI recipients vs 7% of RTV recipients) and adverse events leading to discontinuation of treatment with the study drug (7% vs 7%). Median increases in the serum creatinine level were 0.13 and 0.09 mg/dL, respectively, for COBI and RTV recipients.Conclusions. COBI was noninferior to RTV in combination with ATV plus FTC/TDF at week 48. Both regimens achieved high rates of virologic success. Safety and tolerability profiles of the 2 regimens were comparable. Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor ATV.Clinical Trials Registration. NCT01108510. " 2013 The Author 2013.